tekla life sciences investors is a closed-ended equity mutual fund launched and managed by tekla capital management llc. the fund invests in public equity markets across the globe. it seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. the fund primarily invests in growth stocks of small cap companies. it employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. the fund benchmarks the performance of its portfolio against the nasdaq biotech index and the s&p 500 index. it was form
Company profile
Ticker
HQL
Exchange
CEO
Daniel R. Omstead
Employees
Incorporated
Location
Fiscal year end
Former names
H&Q LIFE SCIENCES INVESTORS
SEC CIK
IRS number
43147016
HQL stock data
Latest filings (excl ownership)
DEF 14A
Definitive proxy
22 Apr 24
N-CEN
Annual report (registered investment company)
12 Dec 23
N-CSR
Certified annual shareholder report (management investment company)
11 Dec 23
DEFA14A
Additional proxy soliciting materials
5 Oct 23
DEFA14A
Additional proxy soliciting materials
3 Oct 23
DEFA14A
Additional proxy soliciting materials
2 Oct 23
POS EX
Additional exhibits for listing
27 Sep 23
DEFA14A
Additional proxy soliciting materials
15 Sep 23
DEFA14A
Additional proxy soliciting materials
15 Sep 23
DEFA14A
Additional proxy soliciting materials
12 Sep 23
Latest ownership filings
4
Boaz Weinstein
23 Apr 24
4
Boaz Weinstein
22 Apr 24
3
Boaz Weinstein
19 Apr 24
SC 13D/A
Saba Capital Management, L.P.
17 Apr 24
4
Kathleen Goetz
12 Apr 24
3
Loretta Tse
22 Mar 24
NPORT-P
abrdn Life Sciences Investors (Dec 2023 report)
29 Feb 24
SC 13D/A
Saba Capital Management, L.P.
7 Feb 24
SC 13D/A
Saba Capital Management, L.P.
12 Jan 24
4
Todd Reit
4 Jan 24
Funds
Series | Ticker | %Monthly Return ? | $Assets | #Holdings | As of | ||
---|---|---|---|---|---|---|---|
TEKLA LIFE SCIENCES INVESTORS | – | -0.66 | -0.89 | -4.15 | 402.59 mm | 140 | Sep 2023 |
Institutional ownership, Q3 2023
25.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 81 |
Opened positions | 11 |
Closed positions | 7 |
Increased positions | 34 |
Reduced positions | 24 |
13F shares | Current |
---|---|
Total value | 76.38 bn |
Total shares | 7.01 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
MS Morgan Stanley | 661.64 k | $8.25 bn |
First Trust Portfolios | 577.69 k | $0.00 |
1607 Capital Partners | 479.42 k | $5.98 bn |
Allspring Global Investments | 347.62 k | $4.33 bn |
Rpo | 327.04 k | $4.08 bn |
Wolverine Asset Management | 322.16 k | $4.02 bn |
Needham Investment Management | 313.79 k | $3.91 bn |
Cornerstone Advisors | 284.63 k | $3.55 bn |
CNH Partners | 272.50 k | $3.40 bn |
Saba Capital Management | 271.61 k | $3.39 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
23 Apr 24 | Saba Capital Management | Common Stock | Buy | Acquire P | Yes | No | 13.15 | 48,203 | 633.87 k | 2,787,195 |
22 Apr 24 | Saba Capital Management | Common Stock | Buy | Acquire P | Yes | No | 12.88 | 2,022 | 26.04 k | 2,738,992 |
19 Apr 24 | Saba Capital Management | Common Stock | Buy | Acquire P | Yes | No | 12.84 | 42,459 | 545.17 k | 2,736,970 |
18 Apr 24 | Saba Capital Management | Common Stock | Buy | Acquire P | Yes | No | 12.8 | 81,738 | 1.05 mm | 2,694,511 |
9 Apr 24 | Kathleen Goetz | Common Stock | Buy | Acquire P | No | No | 13.3183 | 400 | 5.33 k | 1,085.308 |